Rex Fang & Innovation Equity Premium Income ETF vs uniQure N.V. Ordinary Shares — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.99 (market cap $744.46M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FEPI | QURE | |
|---|---|---|
Market Cap | $744.46M | $1.48B |
Volume | 116,338 | 2,488,780 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $70.59 |
52-Week Low | $37.98 | $9.03 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →